Should I buy or sell Arcadia Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RKDA shares. View RKDA analyst ratings or view top-rated stocks .

What is Arcadia Biosciences' stock price target for 2024?

1 analysts have issued 1-year target prices for Arcadia Biosciences' stock. Their RKDA share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 410.2% from the stock's current price. View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts .

How have RKDA shares performed in 2024?

Arcadia Biosciences' stock was trading at $3.13 on January 1st, 2024. Since then, RKDA stock has decreased by 37.4% and is now trading at $1.96. View the best growth stocks for 2024 here .

When is Arcadia Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RKDA earnings forecast .

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its earnings results on Monday, November, 15th. The basic materials company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.13. The basic materials company had revenue of $2.38 million for the quarter, compared to analyst estimates of $2.73 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative trailing twelve-month return on equity of 81.56%. During the same period last year, the company posted ($0.54) earnings per share.

When did Arcadia Biosciences' stock split?

Arcadia Biosciences shares reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com . Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO) , ADMA Biologics (ADMA) , Zosano Pharma (ZSAN) , Gran Tierra Energy (GTE) , Matinas BioPharma (MTNB) , Organigram (OGI) , Pennsylvania Real Estate Investment Trust (PEI) , Novan (NOVN) , CNBX Pharmaceuticals (CNBX) and Enerplus (ERF) .

When did Arcadia Biosciences IPO?

Arcadia Biosciences (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

How do I buy shares of Arcadia Biosciences?

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RKDA

Arcadia Biosciences (RKDA) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free RKDA Stock Alerts

$1.96

-0.07 (-3.45%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.95
▼
$2.08
50-Day Range: $1.89
▼
$3.07
52-Week Range: $1.85
▼
$7.30

Volume: 17,324 shs
Average Volume: 20,272 shs
Market Capitalization: $2.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Arcadia Biosciences alerts:

Arcadia Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 410.2% Upside
$10.00 Price Target
Short Interest: Healthy
0.62% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$1,442 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Arcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Arcadia Biosciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.62% of the float of Arcadia Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Arcadia Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Arcadia Biosciences does not currently pay a dividend.
Dividend Growth
Arcadia Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RKDA.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcadia Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,442.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Arcadia Biosciences is held by insiders.
Percentage Held by Institutions
Only 17.73% of the stock of Arcadia Biosciences is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Arcadia Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcadia Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcadia Biosciences has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Arcadia Biosciences Stock (NASDAQ:RKDA)

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

RKDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RKDA Stock News Headlines

April 17, 2024 | msn.com

SNDL, Arcadia Biosciences among Consumer Staples movers

April 13, 2024 | americanbankingnews.com

Arcadia Biosciences (NASDAQ:RKDA) Now Covered by StockNews.com

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 6, 2024 | markets.businessinsider.com

Buy Rating on Arcadia Biosciences Fueled by Strategic Initiatives and Innovative Product Launches

April 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arcadia Biosciences Amidst Growth and Strategic Shifts

April 1, 2024 | sg.news.yahoo.com

Microsoft unbundles Teams and Office 365 for customers worldwide

April 1, 2024 | finance.yahoo.com

Arcadia Biosciences Full Year 2023 Earnings: Misses Expectations

April 1, 2024 | finance.yahoo.com

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call Transcript

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 30, 2024 | seekingalpha.com

Arcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call Transcript

March 29, 2024 | finance.yahoo.com

Q4 2023 Arcadia Biosciences Inc Earnings Call

March 28, 2024 | sfgate.com

Arcadia Biosciences: Q4 Earnings Snapshot

March 28, 2024 | msn.com

RKDA Stock Earnings: Arcadia Biosciences Beats EPS, Misses Revenue for Q4 2023

March 28, 2024 | benzinga.com

Recap: Arcadia Biosciences Q4 Earnings

March 28, 2024 | businesswire.com

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights

March 23, 2024 | finance.yahoo.com

Arcadia Biosciences, Inc. (RKDA)

March 14, 2024 | finance.yahoo.com

Arcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2023 Financial Results and Business Highlights Conference Call

February 20, 2024 | finance.yahoo.com

Arcadia Biosciences (RKDA) Expands GoodWheat™ Mac & Cheese with Nationwide Availability

February 20, 2024 | businesswire.com

Arcadia Biosciences (RKDA) Expands GoodWheat™ Mac & Cheese with Nationwide Availability

February 16, 2024 | ca.finance.yahoo.com

HYFM Sep 2024 1.000 call

February 14, 2024 | money.usnews.com

Arcadia Biosciences Inc

February 13, 2024 | investing.com

Arcadia Biosciences Inc (RKDA)

December 14, 2023 | markets.businessinsider.com

Buy Rating for Arcadia Biosciences Based on Strategic Initiatives and Product Line Expansion

December 2, 2023 | uk.investing.com

Earnings call: Arcadia Biosciences reports growth driven by GoodWheat and Zola, explores strategic alternatives

December 2, 2023 | morningstar.com

Arcadia Biosciences Inc RKDA

November 28, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights Bunge, The Andersons and Arcadia Biosciences

November 11, 2023 | finance.yahoo.com

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q3 2023 Earnings Call Transcript

See More Headlines

Receive RKDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Basic Materials
Industry: Agricultural production - crops
Sub-Industry: N/A
Current Symbol: NASDAQ:RKDA
CUSIP: N/A
CIK: 1469443
Web: www.arcadiabio.com
Phone: (530) 756-7077
Fax: 530-756-7027
Employees: 30
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +399.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($14.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,980,000.00
Net Margins: -246.80%
Pretax Margin: -246.85%
Return on Equity: -81.56%
Return on Assets: -50.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.17
Quick Ratio: 3.63

Sales & Book Value

Annual Sales: $5.33 million
Price / Sales: 0.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.44 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 1,360,000
Free Float: 1,336,000
Market Cap: $2.72 million
Optionable: Not Optionable
Beta: 0.60

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Stanley E. Jacot Jr. (Age 53)
President, CEO & Director
Comp: $527.9k
Mr. Thomas J. Schaefer (Age 47)
CFO & Corporate Secretary
Mr. Tracy Baker
Senior Vice President of Seamless Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RKDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcadia Biosciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings or view top-rated stocks.
What is Arcadia Biosciences' stock price target for 2024?: 1 analysts have issued 1-year target prices for Arcadia Biosciences' stock. Their RKDA share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 410.2% from the stock's current price.
View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts.
How have RKDA shares performed in 2024?: Arcadia Biosciences' stock was trading at $3.13 on January 1st, 2024. Since then, RKDA stock has decreased by 37.4% and is now trading at $1.96.
View the best growth stocks for 2024 here.
When is Arcadia Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RKDA earnings forecast.
How were Arcadia Biosciences' earnings last quarter?: Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its earnings results on Monday, November, 15th. The basic materials company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.13. The basic materials company had revenue of $2.38 million for the quarter, compared to analyst estimates of $2.73 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative trailing twelve-month return on equity of 81.56%. During the same period last year, the company posted ($0.54) earnings per share.
When did Arcadia Biosciences' stock split?: Arcadia Biosciences shares reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?: 1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Arcadia Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).
When did Arcadia Biosciences IPO?: Arcadia Biosciences (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.
How do I buy shares of Arcadia Biosciences?: Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RKDA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial